HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.

Abstract
We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tuberculosis and included in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia. Efavirenz (600 mg/d) and stavudine plus lamivudine were administered in addition to standard antituberculosis treatment, including rifampicin and isoniazid. Blood samples were obtained a mean of 14 hours after efavirenz intake at weeks 2 and 6 after initiation of efavirenz and weeks 22 (efavirenz plus antituberculosis drugs) and 50 (efavirenz alone) after initiation of antituberculosis treatment. Ten patients participated in an extensive pharmacokinetic study after week 50. CYP2B6 G516T and C485-18T polymorphisms were the most significant covariates, with weight showing a significant minor effect. Change in efavirenz apparent clearance in patients taking both efavirenz and antituberculosis treatment was highly dependent on NAT2 polymorphism, as a possible surrogate of isoniazid exposure. Patients carrying the CYP2B6 516 TT genotype and slow-acetylation NAT2 phenotype had the lowest efavirenz apparent clearance. These data suggest that the inducing effect of rifampicin is counterbalanced by a concentration-dependant inhibitory effect of isoniazid on efavirenz clearance.
AuthorsJulie Bertrand, Céline Verstuyft, Monidarin Chou, Laurence Borand, Phalla Chea, Kuy Huong Nay, François-Xavier Blanc, France Mentré, Anne-Marie Taburet, CAMELIA (ANRS 1295-CIPRA KH001) Study Group
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 209 Issue 3 Pg. 399-408 (Feb 01 2014) ISSN: 1537-6613 [Electronic] United States
PMID23990572 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Alkynes
  • Anti-HIV Agents
  • Antitubercular Agents
  • Benzoxazines
  • Cyclopropanes
  • Lamivudine
  • Stavudine
  • Aryl Hydrocarbon Hydroxylases
  • CYP2B6 protein, human
  • Cytochrome P-450 CYP2B6
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human
  • efavirenz
  • Isoniazid
  • Rifampin
Topics
  • Alkynes
  • Anti-HIV Agents (pharmacokinetics, therapeutic use)
  • Antitubercular Agents (therapeutic use)
  • Aryl Hydrocarbon Hydroxylases (genetics)
  • Arylamine N-Acetyltransferase (genetics)
  • Benzoxazines (pharmacokinetics, therapeutic use)
  • Cambodia
  • Chromatography, Liquid
  • Cyclopropanes
  • Cytochrome P-450 CYP2B6
  • Drug Interactions
  • HIV Infections (complications, drug therapy)
  • Humans
  • Isoniazid (therapeutic use)
  • Lamivudine (therapeutic use)
  • Plasma (chemistry)
  • Polymorphism, Single Nucleotide
  • Rifampin (therapeutic use)
  • Spectrophotometry, Ultraviolet
  • Stavudine (therapeutic use)
  • Tuberculosis (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: